FREELINE THERAPEUTICS HLDGS - SPONSORED ADS (FRLN) Institutional Ownership

CUSIP: 35655L107

13F Institutional Holders and Ownership History from Q3 2020 to Q1 2024

Type / Class
Equity / SPONSORED ADS
Symbol
FRLN
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Investment Quick Answers

What is CUSIP 35655L107?
CUSIP 35655L107 identifies FRLN - FREELINE THERAPEUTICS HLDGS - SPONSORED ADS in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Institutional Holders of FREELINE THERAPEUTICS HLDGS - SPONSORED ADS (FRLN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2024 Q1 0 $0 -$9,326,984 0
2023 Q4 1,466,507 $9,326,984 $6.36 1
2023 Q3 1,466,507 $6,217,990 -$4 $4.24 1
2023 Q2 1,466,508 $3,783,591 -$59,742,505 $2.58 1
2023 Q1 36,854,489 $16,904,846 -$555,491 $0.46 15
2022 Q4 38,057,795 $18,192,005 +$49,718 $0.48 16
2022 Q3 37,948,285 $26,372,000 -$57,772 $0.70 13
2022 Q2 37,990,866 $33,216,000 +$1,800,193 $0.87 16
2022 Q1 13,893,953 $15,492,000 +$1,816,294 $1.12 16
2021 Q4 13,200,510 $25,974,000 -$1,879,119 $1.98 18
2021 Q3 10,610,967 $36,109,000 -$7,787,454 $3.41 19
2021 Q2 11,303,478 $91,623,000 -$4,785,853 $8.15 16
2021 Q1 11,770,309 $144,027,000 -$1,976,258 $12.30 19
2020 Q4 11,923,678 $216,605,000 +$28,323,349 $18.26 20
2020 Q3 9,975,309 $154,754,000 +$154,754,000 $15.61 22